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ABSTRACT
Adult T-cell leukemia (ATL) is an often fatal malignancy caused by infection 
with the complex retrovirus, human T-cell Leukemia Virus, type 1 (HTLV-1). In ATL 
patient samples, the tumor suppressor, p53, is infrequently mutated; however, it has 
been shown to be inactivated by the viral protein, Tax. Here, we show that another 
HTLV-1 protein, HBZ, represses p53 activity. In HCT116 p53+/+ cells treated with the  
DNA-damaging agent, etoposide, HBZ reduced p53-mediated activation of  
p21/CDKN1A and GADD45A expression, which was associated with a delay in 
G2 phase-arrest. These effects were attributed to direct inhibition of the histone 
acetyltransferase (HAT) activity of p300/CBP by HBZ, causing a reduction in 
p53 acetylation, which has be linked to decreased p53 activity. In addition, HBZ 
bound to, and inhibited the HAT activity of HBO1. Although HBO1 did not acetylate  
p53, it acted as a coactivator for p53 at the p21/CDKN1A promoter. Therefore, through 
interactions with two separate HAT proteins, HBZ impairs the ability of p53 to activate 
transcription. This mechanism may explain how p53 activity is restricted in ATL cells 
that do not express Tax due to modifications of the HTLV-1 provirus, which accounts 
for a majority of patient samples.
INTRODUCTION
The tumor suppressor, p53, is a central regulator 
of genome stability in mammalian cells. Following DNA 
damage, p53 becomes acetylated and phosphorylated 
at multiple sites, thereby shifting the protein from an 
unstable, latent form to one that is stable, active and 
concentrated in the nucleus [1]. This transition allows 
p53 to bind to promoters of genes involved in cell cycle 
arrest, such as p21/CDKN1A and GADD45A, and 
activate their transcription [2–4]. p53 is also able to 
regulate expression of genes involved in the DNA damage 
response, apoptosis and in its own regulation [5, 6]. 
Although certain posttranslational modifications may serve 
redundant functions, there appears to be separate patterns 
of acetylation and phosphorylation of p53 that favor 
either cell cycle arrest and DNA repair or, alternatively, 
apoptosis [6]. Regardless of these complexities, it is clear 
that acetylation of p53 is essential in promoting either of 
the two cellular fates [7].
In general, acetylation has been shown to augment 
the transcriptional activity and stability of p53. For 
example, acetylation of lysine residues within the 
C-terminal domain of the protein have been found 
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to induce conformational changes that may enhance 
DNA-binding activity and interactions with other 
transcriptional regulatory proteins [8–10]. In addition, 
acetylated lysine residues in p53 may be shielded from 
ubiquitination by Mdm2 and other E3 ubiquitin ligases 
that mark p53 for proteosomal degradation [11, 12]. 
Furthermore, these modified lysine residues may enhance 
interactions between p53 and coactivators, thereby 
facilitating the recruitment of these coactivators to 
promoters [13, 14].
p300 (also designated KAT3B), was the first histone 
acetyltransferase (HAT)-carrying protein found to acetylate 
p53 [9]. Of the six HAT proteins reported to acetylate p53, 
p300 is responsible for the most extensive acetylation 
of this factor, modifying five lysine residues in the 
C-terminal domain of p53 (K370, K372, K373, K381 and 
K382) [9], one lysine residue in the DNA-binding domain 
(K164) [7], and one lysine residue positioned between 
these two domains (K305) [15]. This observation implies 
an important role for p300 in regulating p53 activity, 
as acetylation of different lysine residues in p53 may elicit 
redundant effects [10], and at least partial acetylation of 
p53 is required for its transcriptional activity. Acetylation 
of p53 by p300 frequently contributes to activation of 
p21/CDKN1A expression, promoting cell cycle arrest, 
while effects on apoptotic gene expression, such as that of 
PUMA, appear to vary with cell type [16]. In addition to 
directly modifying p53, p300 contributes to p53-mediated 
transcriptional activation via its coactivator function and 
through histone acetylation at promoters bound by p53.
Another HAT-containing protein, histone 
acetyltransferase bound to ORC1 (HBO1, KAT7, MYST2), 
also interacts directly with p53 [17]. Unlike p300, HBO1 
has not been reported to acetylate p53, even though it is 
involved in activating transcription of p53-responsive 
genes, including p21/CDKN1A [18]. HBO1 has also been 
shown to contribute to transcriptional activation through 
interactions with hormone nuclear receptors and AP-1 
transcription factors [19–21]. Outside of its transcriptional 
functions, HBO1 helps modulate replication by serving as 
a coactivator for the replication licensing factor, CDT1 
[22, 23]. In this context, HBO1 loading onto the chromatin 
promotes chromatin structure remodeling and subsequent 
recruitment of putative DNA helicase MCM2-7 [23].
Given the fundamental role of p53 in maintaining 
genome stability, in more than half of all cancers, it is 
functionally disabled through mutation [24]. In those cancer 
cells that retain wild-type p53, defects frequently occur in 
other components required for proper p53 function [6]. 
For example, multiple types of leukemia/lymphoma 
show a high frequency of mutations within the genes 
encoding p300 and CBP that abolish the HAT activities 
of these homologous proteins and prevent full acetylation 
of p53 [25–27]. Furthermore, tumor viruses have evolved 
mechanisms to inhibit p53 activity. One example is 
the complex retrovirus, human T-cell Leukemia Virus 
type 1 (HTLV-1), which is the etiologic agent of adult 
T-cell leukemia (ATL), a fatal malignancy characterized 
by uncontrolled proliferation of CD4+ T-cells [28]. While 
most ATL cells express wild-type p53 [29, 30], the function 
of the tumor suppressor is consistently impaired [31]. This 
effect has been attributed to the HTLV-1-encoded protein, 
Tax [32], which has been reported to inhibit p53 activity 
either by stimulating NF-κB signaling or by sequestering 
p300/CBP from p53, or through a separate, undefined 
mechanism [33–36]. In lieu of these reports, ATL cells 
from most patients do not express Tax due to deletion or 
methylation of the 5′ long terminal repeat (LTR) of the 
HTLV-1 provirus [37–39] which regulates expression of 
the tax gene and all other viral genes with the exception 
of hbz [28]. The hbz gene is consistently expressed in ATL 
cells [40, 41], as it is encoded on the negative strand of the 
provirus and regulated by a promoter in the 3′ LTR that 
does not undergo the same modifications as the 5′ LTR 
[28, 42]. This gene encodes the nuclear protein, HTLV-1 
basic leucine zipper (bZIP) factor (HBZ) [42].
We previously found that HBZ interacts with 
multiple domains of p300/CBP, including the HAT 
domain [43]. The binding of HBZ to the HAT domain 
inhibits its enzymatic activity, which reduces p53 
acetylation following induction of DNA damage [44]. 
In the current study, we evaluate the effect of HBZ on 
p53 transcriptional activity. Using HCT116 cells, in 
which the p53 signaling pathway is intact, we found that 
HBZ reduces transcription of the p53-responsive genes, 
p21/CDKN1A and GADD45A, which contribute to cell 
cycle arrest. Mechanistically, this effect occurs through 
inhibition of the HAT activities of both p300 and HBO1. 
Functionally, this effect delays the onset of G2/M arrest 
induced by etoposide. These results indicate that HBZ 
contributes to the loss of function of p53 observed during 
HTLV-1 infection and maintains p53 in an inactive state in 
ATL cells lacking other viral proteins.
RESULTS
HBZ inhibits p53 transcriptional activity on 
specific genes
We previously showed that HBZ inhibits p53 
acetylation by the homologous coactivators, p300 and 
CBP [44]. Given that this modification contributes to the 
transcriptional activity of p53 following DNA damage 
[16], it was possible that HBZ repressed expression 
of genes activated by p53. To test this hypothesis, we 
analyzed expression of p53-responsive genes in HCT116 
cells that express wild type p53 (p53+/+) and are commonly 
used to study the p53 pathway. In addition to p300 and 
CBP, other HAT-containing proteins acetylate p53 [16], 
and using western blot analysis, we confirmed that these 
proteins are expressed in the HCT116 cell line (Figure 1A). 
To examine potential effects of HBZ on expression of 
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p53-responsive genes, we transfected cells with either 
an empty vector or an expression vector for the HBZ 
splice 1 isoform (herein referred to as HBZ), which 
is the predominant isoform expressed in ATL cells 
[41, 45]. Etoposide was then used to induce p53 
acetylation and activation [8], and RNA was extracted 
and subjected to quantitative RT-PCR analysis. The 
p53-responsive genes tested included those involved 
in cell cycle inhibition (p21/CDKN1A, GADD45A), 
regulation of p53 (MDM2, PIRH2), the DNA damage 
response (GADD45, RRM2B), and induction 
of apoptosis (BID, FAS, PUMA, NOXA, BAX) 
[46]. As expected, etoposide treatment increased H2A.X 
phosphorylation, consistent with the induction of DNA 
damage (Figure 1A), and activated transcription of most 
of the p53-reponsive genes (Figure 1B). While a general 
trend was observed in which cells expressing HBZ 
exhibited a reduction in the mRNA levels of the genes 
tested, this effect was only significant for p21/CDKN1A 
and GADD45A. Consistent with this effect, HBZ also 
decreased p21/CDKN1A protein abundance following 
etoposide treatment (Figure 1A). In untreated cells, HBZ 
did not reduce the basal expression of these genes (data 
not shown), which is the same result found with mouse 
T-cells transiently expressing HBZ [47]. These results 
suggest that HBZ affects the expression of only a subset of 
p53-responsive genes with overlapping functions in 
cell cycle inhibition. We also confirmed that etoposide 
treatment did not affect the nuclear levels of the HATs 
(Figure 1A, lanes 2 and 4). In these experiments the 
transfection efficiency was estimated to be approximately 
50%. Consequently, the reduction in p21/CDKN1A 
and GADD45A mRNA was more pronounced when 
comparing a HeLa clonal cell line stably expressing HBZ 
to a clonal cell line carrying the empty vector (Figure 1C).
Considering that the oncogenic effects caused 
by HTLV-1 infection arise in a T-cell environment, 
we tested whether HBZ also reduced the extent of 
p21/CDKN1A and GADD45A activation in the MOLT-4 
T-cell line. While the status of p53 appears to vary among 
different sources of this line [48, 49], the cells we tested 
express the p53 protein [50, 51] and display activation of 
p21/CDKN1A and GADD45A expression following 
etoposide treatment. In analyzing cells transduced with HBZ 
versus cells transduced with the empty expression vector, we 
observed a smaller increase in the levels of p21/CDKN1A 
and GADD45A mRNA in the presence of HBZ (Figure 1D), 
consistent with results obtained using HCT116 and HeLa 
cells. As with the transfected HCT116 cells, the modest effect 
of HBZ may be due to a limited transduction efficiency.
HBZ inhibits p21/CDKN1A transcription by 
inhibiting p300 and HBO1 activity
We next examined whether an inhibitory effect 
of HBZ on one or more of the HAT proteins reduces 
transcription from the p21/CDKN1A promoter. The HAT 
proteins p300, p/CAF (KAT2B), MOZ (KAT6A, MYST3) 
and Tip60 (KAT5) participate in the activation of 
p21/CDKN1A expression, in part through acetylation of 
p53 [16]. In addition, the HAT protein, HBO1, contributes 
to the activation of p21/CDKN1A expression through 
a p53-dependent mechanism, but has not been reported 
to acetylate p53 [18]. In experiments, we cotransfected 
HCT116 cells with an expression vector for each HAT 
protein and the WWP-Luc reporter construct, which 
contains the p21/CDKN1A promoter, encompassing 
the p53 responsive elements, upstream of the luciferase 
gene [2]. Ectopic expression of p300, MOZ and HBO1 
led to a significant increase in luciferase activity, while 
expression of p/CAF and Tip60 did not (Figure 2A). 
We additionally analyzed luciferase activity in cells 
ectopically expressing both p300 and one of each of 
the other HAT proteins. This approach was used to test 
whether p300 modulates the effects of other HAT proteins 
at the p21/CDKN1A promoter, as p300 has been shown to 
regulate acetylation of the FoxP3 transcription factor by 
Tip60 [52]. Interestingly, only expression of HBO1 with 
p300 increased the level of activation beyond that of p300 
alone (Figure 2A). This increase appeared to be additive, 
suggesting that these two HATs have distinct functions in 
the regulation of p21/CDKN1A expression.
Based on these results, we performed additional 
reporter assays to test whether HBZ inhibits the effects 
of p300 and HBO1 at the p21/CDKN1A promoter. 
Interestingly, co-transfection of the HBZ expression 
vector prevented both HAT proteins from activating 
luciferase transcription (Figure 2B, lanes 3 and 6). We also 
analyzed the effects of a bZIP deletion mutant of HBZ 
(HBZ–ΔbZIP) based on previous data showing that the 
bZIP domain of HBZ inhibits p300 HAT activity through 
a direct interaction with the HAT domain [44]. In contrast 
to full-length HBZ, HBZ-ΔbZIP did not block activation 
from the promoter by either p300 or HBO1 (Figure 2B, 
lanes 4 and 7). In the absence of exogenous p300 and 
HBO1, both HBZ and HBZ-ΔbZIP caused a reduction in 
luciferase activity. This effect was not investigated further, 
but may arise from the interaction between HBZ and the 
KIX domain of p300 [43].
We also examined the effects of HBZ on transcription 
from the p21/CDKN1A promoter in Jurkat T-cells. In reporter 
assays, cells were co-transfected with a p53 expression 
plasmid, as Jurkat cells lack endogenous p53 expression 
[53, 54]. Interestingly, HBZ did not affect the level of basal 
transcription induced by p53 in the absence of stimulation 
(Figure 3C, lanes 3 and 4). However, we found that etoposide-
mediated activation of transcription from the p21/CDKN1A 
promoter was abrogated in presence of HBZ, but was retained 
in the presence of HBZ-ΔbZIP (Figure 3C, lanes 6 and 7). 
These observations are consistent with the results obtained 
using HCT116 cells and indicate that HBZ is able to inhibit 
p53 transcriptional activity in a T-cell environment. 
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HBZ inhibits acetylation of p53 at lysine K382 
by p300/CBP
We previously showed that HBZ reduces 
p53 K382 acetylation in HeLa cells [44]. These cells are 
transformed by human papilloma virus 18 and therefore 
express the viral protein E6 which also inhibits p53 
activity [55]. To confirm that HBZ is able to reduce p53 
K382 acetylation independent of this other viral protein, 
we transfected the HCT116 cells with the HBZ expression 
vector and subsequently treated the cells with etoposide 
or other genotoxic agents to induce p53 acetylation 
[12, 56]. Consistent with our previous results, we observed 
a reduction in p53 K382 acetylation in the presence 
of HBZ (Figure 3A). However, HBZ did not affect 
acetylation of K320, which is a substrate for p/CAF [57], 
and K120, which is a substrate for Tip60, MOF and MOZ 
[58–60] (Figure 3A).
To verify that the reduction in K382 acetylation 
was a specific effect of HBZ, we tested whether another 
HTLV-1-encoded protein, Tax, affected the level of 
acetylation of this residue. Tax has been reported to 
repress p53 activity through multiple mechanisms that 
do not directly involve p53 acetylation [33–36]. As 
expected, expression of Tax in HCT116 cells treated with 
etoposide did not lead to an alteration in K382 acetylation 
Figure 1: HBZ inhibits p53-mediated activation of p21/CDKN1A and GADD45A. HCT116 p53+/+ cells were transiently 
transfected with an HBZ or empty expression vector and treated with etoposide (ETO) or the DMSO vehicle control (control) for 
8 hours. A. Expression of HAT proteins. Nuclear extracts were analyzed by Western blot using the antibodies indicated. B. mRNA levels of 
p53-responsive genes. The graph shows real-time PCR data averaged from three or more independent experiments ± S.D. C. mRNA 
levels of p21/CDKN1A and GADD45A genes. HeLa cells stably transfected with an HBZ or empty expression vector and treated with 
etoposide (ETO) or the DMSO vehicle control (control) for 6 hours. The graph shows real-time PCR data averaged from four independent 
experiments ± S.D. *P < 0.05; **P < 0.005 (two-tailed Student t test). D. p21/CDKN1A and GADD45A mRNA levels from MOLT-4 cells 
transduced with pBABE-GFP-HBZ or pBABE-GFP. The graph shows real-time PCR data averaged from two independent experiments 
± S.D.
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(Figure 3B), suggesting that HBZ regulates p53 activity in 
a distinct manner from that of Tax.
Given that both p300/CBP and MOZ have been 
reported to acetylate K382 of p53 [9, 60], we were 
interested in determining which HAT protein is targeted 
by HBZ. In order to differentiate between p53 acetylation 
by p300 and MOZ, we performed in vitro HAT assays 
using recombinant proteins. We found that both p300 and 
MOZ acetylated histones, indicating that both proteins 
were enzymatically active (Figure 3C). However, only 
p300 acetylated p53 at K382 (Figure 3D, top panel). As 
this result was unexpected, we used a pan-acetyl-lysine 
Figure 2: HBZ represses transcription from the p21/CDKN1A promoter through inhibition of p300 and HBO1. 
A. p300 and HBO1 produce an additive increase in transcription from the p21/CDKN1A promoter. HCT116 p53+/+ cells were cotransfected 
with p21-luc (200 ng), and expression vectors for Flag-p300 (400 ng), Flag-p/CAF (50 ng), Flag-MOZ (400 ng), HA-HBO1 (400 ng), 
or HA-Tip60 (50 ng) as indicated. The graph shows average luminescence values ± S.D. from one experiment performed in triplicate 
and is representative of three independent experiments. Cellular lysates used for the luciferase assay were also analyzed by Western blot 
using the antibodies indicated. # denotes a crossreactive protein or truncated product; ∆ denotes a crossreactive protein. B. HBZ inhibits 
p300- and HBO1-mediated activation of transcription from the p21/CDKN1A promoter. HCT116 p53+/+ cells were cotransfected with p21-luc 
(200 ng) and expression vectors for Flag-p300 (400 ng), HA-HBO1 (400 ng), HBZ-Myc-His and/or HBZ-∆bZIP-Myc-His as indicated. The 
graph shows average luminescence values ± S.D. from one experiment performed in triplicate and is representative of three independent 
experiments. Cellular lysates used for the luciferase assay were also analyzed by Western blot using the antibodies indicated. *P < 0.05; 
**P < 0.005 (two-tailed Student t test). C. HBZ inhibits etoposide-mediated activation of transcription from p21/CDKN1A promoter in 
T-cells. Jurkat T-cells were cotransfected with p21-luc (200 ng) and expression vectors for p53 (25 ng), HBZ-Myc-His and/or HBZ-∆b 
ZIP-Myc-His (800 ng) as indicated. Cells were treated with etoposide for 5 hours prior to harvesting. The graph shows average 
luminescence values ± S.D. from one experiment performed in triplicate and is representative of two independent experiments. *P < 0.05 
(two-tailed Student t test).
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antibody in the assay and detected weak p53 acetylation 
by MOZ in comparison to strong acetylation by p300, 
which is known to acetylate at least eight lysine residues 
[16] (Figure 3D, middle panel). This observation confirms 
acetylation of p53 by MOZ, suggesting that in our 
in vitro assays, acetylation of p53 by MOZ is restricted to 
K120. Consistent with our previous study [44], addition 
of full-length HBZ or the bZIP domain of HBZ reduced 
K382 acetylation by p300, while addition of the activation 
domain of HBZ did not affect acetylation (Figure 3E). As 
previously observed, HBZ was acetylated in the reaction 
[44]. These data suggest that inhibition of p300 HAT 
activity by HBZ is responsible for the reduction in p53 
K382 acetylation in the HCT116 cells, which contributes 
to HBZ-mediated repression of transcription from the 
p21/CDKN1A promoter. 
HBO1 is a coactivator of p53 transcription
In addition to affecting p300, HBZ also blocked the 
effects of HBO1 at the p21/CDKN1A promoter. In order 
to define the mechanism of inhibition, it was important to 
first determine the function of HBO1 at the p21/CDKN1A 
promoter. Previously, HBO1 was found to be associated 
with the p21/CDKN1A promoter, and shRNA-mediated 
knockdown of p53 reduced transcriptional activation by 
HBO1, suggesting that HBO1 activity was dependent on 
p53 [18]. However, in a separate study, p53 was found 
to bind to, and inhibit the HAT activity of HBO1 [17]. 
Consequently, we first tested whether HBO1 positively 
or negatively affected p53 transcriptional activity from 
a synthetic p53 responsive reporter plasmid (pG13-Luc), 
using the p53-negative cell line, H1299. As expected, 
transfection of increasing amounts of an HBO1 expression 
vector did not activate transcription in the absence of p53 
(Figure 4A). However, co-transfection of a p53 expression 
vector led to a dose-depend increase in transcription in 
response to HBO1, an effect that was abrogated by 
substituting wild-type HBO1 with a HAT-defective 
mutant, HBO1G485 [17, 61] (Figure 4A). 
Based on these results, we used chromatin 
immunoprecipitation (ChIP) assays to test whether p53 
facilitates recruitment of HBO1 to the p21/CDKN1A and 
GADD45A promoters. In HCT116 cells, p53 activation by 
treatment with etoposide increased the level of enrichment 
of both p53 and HBO1 at both promoters (Figure 4B). 
This effect was not due to an increase in HBO1 
expression (Figure 4D). In contrast to the p21/CDKN1A 
and GADD45A promoters, the signal for both proteins 
remained close to background at the BDNF promoter, 
which is not regulated by p53 (Figure 4B). In H1299 
cells, HBO1 was enriched at the HoxA9 promoter, as we 
showed previously [23], but not at the p21/CDKN1A and 
GADD45A promoters, regardless of etoposide treatment 
(Figure 4C).
We also tested whether HBO1 activated endogenous 
expression of p21/CDKN1A and GADD45A. Using 
HCT116 cells we found that treatment with etoposide 
caused an increase in the level of p21/CDKN1A 
and GADD45A mRNA; however, this increase was 
significantly reduced by siRNA-mediated knockdown of 
HBO1 expression (Figure 4E). Overall, the results above 
indicate that HBO1 is recruited to the p21/CDKN1A 
and GADD45A promoters where it participates in the 
activation of p53-mediated transcription via its HAT 
activity.
HBZ inhibits HBO1 HAT activity
Previous results from a yeast two-hybrid 
analysis revealed that HBO1 interacts with HBZ 
[62]. To confirm this finding in mammalian cells, we 
co-transfected HEK293T/17 cells with expression 
vectors for HBO1 and HBZ and found that each protein 
was coimmunoprecipitated with the other (Figure 5A). 
In addition, in H1299 cells, endogenous HBO1 was 
coimmunoprecipitated with ectopically expressed HBZ 
(Figure 5B). Together, these results suggest that HBZ 
and HBO1 interact in a p53-independent manner. Using 
a GST pull-down assay, we showed that GST fused to 
full-length HBZ or the bZIP domain alone bound directly 
to HBO1 (Figure 5C). These results indicate that the direct 
interaction between HBZ and HBO1 is, in part, mediated 
through the bZIP domain of the viral protein.
Considering that the bZIP domain of HBZ is 
sufficient to inhibit p300 HAT activity through a direct 
interaction with the coactivator [44], it was possible that 
HBZ also inhibited the HAT activity of HBO1. To test 
this hypothesis, we performed in vitro HAT assays using 
recombinant histones as substrates. In comparison to p300, 
HBO1 HAT activity was weaker and favored histone H4 
(Figure 5D, lanes 2 and 3). Consistent with our hypothesis, 
both full-length HBZ and the bZIP domain alone inhibited 
HBO1 HAT activity, while the activation domain of HBZ 
did not (Figure 5D, lanes 5–7). Unlike histones H3 and 
H4, p53 was not acetylated by HBO1 (Figure 5E).
Using H1299 cells and the pG13-Luc reporter 
plasmid we then tested whether HBZ inhibits p53 
transcriptional activity augmented through HBO1. In the 
absence of HBZ, p53 increased luciferase activity, which 
was further elevated by ectopic expression of HBO1, 
but not by HBO1G485 (Figure 5F, lanes 1, 3, 5 and 7). 
Consistent with a previously study [63], HBZ did not 
affect the activation of transcription by p53 alone (Figure 
5F, lane 4); however, HBZ did inhibit the activation of 
transcription coordinated through p53 and HBO1 together 
(Figure 5F, lane 6).
While the effect on transcription is expected to stem 
from the inhibition of HBO1 HAT activity, it was possible 
that HBZ additionally influenced the recruitment of HBO1 
Oncotarget1693www.impactjournals.com/oncotarget
to the p21/CDKN1A promoter. To test this hypothesis, we 
used ChIP assays to compare levels of HBO1 enrichment 
at the promoter in a HeLa clonal cell line expressing HBZ 
and one carrying the empty vector [64]. We analyzed 
amplicons corresponding to the p53 responsive elements 
in the promoter, the transcription start site and a distal 
coding region (Figure 6A). In absence of HBZ, etoposide 
treatment led to enrichment of HBO1 at the distal and 
proximal p53 responsive elements, and more substantially, 
at the transcription start site as previously reported 
(Figure 6B, [18]). In comparison, cells expressing HBZ 
exhibited a lower level of HBO1 enrichment at the 
transcription start site following etoposide treatment 
(Figure 6C). These results suggest that HBZ, in addition 
to inhibiting the HAT activity, may also interfere with the 
recruitment of HBO1 to the promoter in proximity of the 
transcription start site. 
HBZ delays cell cycle arrest induced by 
etoposide treatment
Our data indicate that HBZ does not affect 
p53-mediated activation of pro-apoptotic genes and 
does not alter levels of p53 K120 acetylation, which is 
Figure 3: HBZ inhibits acetylation of p53 K382. A. and B. HCT116 p53+/+ cells were transiently transfected with an HBZ, Tax 
or an empty expression vector and, 48 h post-transfection, were treated with etoposide (ETO), actinomycin D (ACT.D), doxorubicin 
(DOX) or the DMSO vehicle control (−) for 8 hours as indicated. Nuclear extracts were prepared and analyzed by Western blot using 
the antibodies indicated. C. Acetylation of histone H4 by p300 and MOZ. In vitro HAT assays were performed using recombinant 
histones (2 µM), p300 (2 nM) and MOZ-HAT (0.15 µM) and analyzed by Western blot using antibodies against histone H4 and acetylated 
histone H4 as indicated. D. Acetylation of p53 by p300 and MOZ. In vitro HAT assays were performed using the same concentrations of 
recombinant proteins as above, but with p53 (0.1 µM) replacing histones as the substrate. Reactions were analyzed by western blot using 
antibodies against acetylated lysine, p53 acetyl-K382 and p53. E. HBZ inhibits acetylation of p53 by p300. In vitro HAT assays were 
performed using recombinant p300 (2 nM), p53 (25 nM) and supplemented with GST (0.3 µM), GST-HBZ (0.3 µM), HBZ-AD (0.3 µM) or 
HBZ-bZIP (0.3 µM) where indicated. Reactions were analyzed by Western blot using antibodies against acetylated lysine, p53 acetyl-K382 
and p53. Identical quantities from the same batch of proteins used in the HAT assay were resolved by SDS-PAGE and stained with 
Coomassie (lower panel).
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associated with induction of apoptosis. To extend these 
findings, we compared apoptotic cell populations between 
HCT116 cells transfected with the HBZ or the empty 
expression vector following etoposide treatment. As 
expected, Annexin V and/or propidium iodide staining did 
change significantly in the presence of HBZ, supporting 
that HBZ does not suppress induction of apoptosis by 
p53 (Figure 7A). It is important to note that, in these 
experiments, dead cells were removed from cultures just 
prior to the addition of etoposide. Indeed, while the HBZ 
protein has also been reported to attenuate apoptosis [65], 
results from one study have shown that the HBZ protein 
induces apoptosis [66].
Finally, we were interested in determining whether 
inhibition of p21/CDKN1A expression by HBZ is 
associated with a reduction in p21/CDKN1A function. 
p21/CDKN1A induces cell cycle arrest at the G1/S 
[2, 3, 67] and G2/M checkpoints [68–73]. In addition, 
Figure 4: HBO1 contributes to p53-mediated activation of p21/CDKN1A. A. HBO1 augments p53-dependent transcription. H1299 
cells were cotransfected with pG13-luc (150 ng), and expression vectors for HA-p53 (200 ng), Flag-HBO1 (increasing concentration up to 
1 μg), Flag-HBO1G485 (increasing concentration up to 1 μg), or a combination of those as indicated. The graph shows relative luminescence 
values ± S.D. from a triplicate experiment. Data are normalized to the control condition artificially set to 1 (lane 1 for the graph on the 
left and lane 6 for the graph on the right). B. Etoposide induces HBO1 recruitment to the p21/CDKN1A and GADD45A promoters. 
Chromatin immunoprecipitation (ChIP) analysis was performed on chromatin prepared from untreated HCT116 p53+/+ cells (grey bars) 
or cells treated with etoposide (black bars) using p53 and HBO1 antibodies or a preimmune serum (IgG). Precipitated DNA fragments 
were subjected to real-time PCR analysis with primers amplifying the BNDF promoter, the p53 binding region in the p21/CDKN1A 
promoter and the GADD45A promoter. Data are presented as fold enrichment over a control unrelated regions. C. HBO1 recruitment to the 
p21/CDKN1A and GADD45A promoters is dependent on p53. ChIP analysis in H1299 cells untreated (grey bars) or treated with etoposide 
(black bars) using an HBO1 antibody or a preimmune serum (IgG). Precipitated DNA fragments were subjected to real-time PCR analysis 
with primers amplifying the BNDF promoter, the p53 binding region in the p21/CDKN1A promoter, the GADD45A promoter and an 
HBO1 binding site in the HOXA9 promoter. D. Characterization of H1299 and HCT116 p53+/+ cells used in the study by Western blot. 
E. HBO1 depletion reduces transcription of p21/CDKN1A and GADD45A induced by etoposide. RT-PCR analyses of p21/CDKN1A and 
GADD45A expression were performed on mRNAs prepared from HCT116 cells transiently transfected with a specific siRNA against 
HBO1 or a control siRNA and further treated with ETO or not. Expression in each condition is normalized to the condition: -ETO, NT. 
F. The efficiency of the siRNA was estimated by Western blot.
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GADD45A also promotes G2 arrest [74–76], and as 
shown in Figure 1, its expression is reduced by HBZ 
following etoposide treatment. To test whether HBZ 
influences the G2/M checkpoint, we analyzed the effects 
of the viral protein on etoposide-mediated cell cycle arrest 
in HCT116 cells. In asynchronous cells, HBZ appeared 
to reduce the sensitivity of cells to etoposide following 
24 hours of treatment, as less HBZ-expressing cells 
occupied G2 phase compared to cells transfected with 
the empty expression vector (Figure 7B). However, it 
was possible that this effect was due to a difference in 
proliferation between HBZ and empty vector cells, as 
HBZ has been shown to increase T-cell proliferation [40, 
77]. Therefore, to show that results were specifically 
due to a difference in cell cycle arrest, we repeated 
experiments using synchronized cells and evaluated the 
effects of etoposide at different time points. Following 24 
hours of etoposide treatment, we again observed less HBZ-
expressing cells in G2 compared with cells carrying the 
empty vector; however at 36 hours of treatment, the HBZ-
expressing cells appeared to arrest in G2 (Figure 7C). 
Together, the results above indicate that HBZ delays G2/M 
arrest induced by DNA damage. 
DISCUSSION
In this study we provide evidence that HBZ reduces 
p53-mediated activation of the cell cycle arrest genes, 
p21/CDKN1A and GADD45A, following etoposide 
Figure 5: HBZ inhibits HBO1 HAT activity. A. HBZ and HBO1 interact in vivo. Whole cell extracts were prepared from 
HEK293T/17 cells transfected with expression vectors for HBZ-Myc-His and/or HBO1-HA (6 µg of each vector). Extracts were analyzed by 
immunoprecipitation (IP) and Western blotting using Myc and HA epitope antibodies as indicated. Whole cell extracts (10% of the IP inputs) 
are shown in lanes 1 to 3. B. HBZ interacts with endogenous HBO1. Nuclear extract was prepared from H1299 cells transfected with 
an expression vector for HBZ-Flag (3 µg) and analyzed by IP using preimmune serum (IgG) or a Flag epitope antibody as indicated. 
The Western blot was probed with Flag and HBO1 antibodies. The nuclear extract (20% of the IP input) is shown in lane 1. C. HBZ and 
HBO1 interact directly. Recombinant HBO1 (10 pmol) was incubated with 25 pmol of GST, GST-HBZ or GST-bZIP. Bound proteins were 
detected by Western blot using 6xHis and GST antibodies. A fraction of the HBO1 input (10%) is shown in lane 1. D. HBZ inhibits HBO1 
HAT activity. In vitro HAT assays were performed using recombinant histones (2 μM), p300 (2 nM), HBO1 (18 nM), GST (0.2 µM), 
GST-HBZ (0.2 µM), HBZ-AD (0.2 µM) and HBZ-bZIP (0.2 µM) as indicated and analyzed by Western blot using antibodies against 
acetylated lysine, acetylated histone H4 and histone H4 as indicated. E. HBO1 does not acetylate p53. In vitro HAT assays were performed 
using the same concentrations of the indicated recombinant proteins as above, but with p53 (0.1 µM) replacing histones as the substrate. 
Reactions were analyzed by Western blot using antibodies against acetylated lysine and p53. Only a portion of the HAT assay was loaded 
in lane 2. F. HBZ inhibits HBO1-mediated activation of the p21/CDKN1A promoter. H1299 cells were cotransfected with pG13-luc 
(150 ng), and expression vectors for HA-p53 (200 ng), Flag-HBZ (150 ng), Flag-HBO1 (200 ng), Flag-HBO1G485 (200 ng), or combination 
of those as indicated. The graph shows relative luminescence values ± S.D. from a triplicate experiment. Data are normalized to the control 
condition (lane 1) artificially set to 1. *P < 0.05 (two-tailed Student t test).
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treatment. Analysis of the p21/CDKN1A promoter in 
reporter assays corroborated that repression by HBZ 
occurred at the level of transcription and involved 
repression of the HAT activities of p300 and HBO1.
In the case of p300, HBZ inhibited its ability to 
directly acetylate p53. In addition to acting as a coactivator 
for p53, p300 acetylates multiple lysine residues in p53, 
including those in the C-terminal domain (K370, K372, 
K373, K381 and K382) that, when acetylated, enhance the 
DNA binding activity of p53 [9]. We found that expression 
of HBZ consistently dampened K382 acetylation of p53 
in response to various DNA damaging agents. In contrast, 
HBZ did not appear to inhibit the HAT activities of other 
proteins known to modify p53. Specifically, HBZ did not 
appear to affect acetylation of K120, which is targeted 
by either Tip60, MOF or MOZ [58–60], nor did it appear 
Figure 6: HBZ inhibits binding of HBO1 to the p21/CDKN1A promoter following etoposide treatment. A. Graphic 
representation of the p21/CDKN1A promoter showing 5′ and 3′ p53 responsive elements (RE, white boxes) and the transcription start 
site (TSS). Bold horizontal lines denote real-time PCR amplicons. ChIP analyses were performed on chromatin prepared from untreated 
(grey bars) or etoposide-treated (black bars) cells using an HBO1 antibody or a preimmune serum (IgG). Precipitated DNA fragments were 
subjected to real-time PCR analysis. Data are presented as fold enrichment over a control unrelated regions. B. Analysis of a HeLa clonal 
cell line containing the empty pcDNA 3.1 vector. C. Analysis of a HeLa clonal cell line stably expressing HBZ.
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to affect acetylation of K320, which is a substrate for 
p/CAF [57]. In addition to p300, MOZ has been reported 
to acetylate p53 at K382 [60]. We confirmed that HBZ 
represses K382 acetylation by p300 in in vitro HAT 
assays [44]. However, we were unable to detect K382 
acetylation by MOZ in these assays despite the ability of 
the recombinant, purified polypeptide to acetylate histone 
proteins. Considering that we tested a truncated form of 
MOZ (amino acids 497–780), encompassing the HAT and 
acidic domains, it is possible that the p53 interaction is 
mediated through a separate region of MOZ. Nevertheless, 
we speculate that K382 acetylation in HCT116 cells 
occurs primarily through p300 given that p300 elicited 
a significantly greater increase in transcription from the 
p21/CDKN1A promoter than MOZ in luciferase assays.
Interestingly, HBZ also repressed transcription 
from the p21/CDKN1A promoter through inhibition of 
HBO1. Recently, HBO1 was shown to localize to the 
p21/CDKN1A promoter and activate transcription in 
a p53-dependent manner [18]. This effect is likely to 
involve a direct interaction between HBO1 and p53 that 
was separately characterized [17]. Indeed, we observed 
that HBO1 is recruited to the p21/CDKN1A promoter in 
a p53-dependent manner and that the ability of HBO1 
to augment transcriptional activity of p53 requires the 
functional HAT domain. Our results indicate that HBZ 
Figure 7: HBZ delays cell cycle arrest in G2/M following treatment with etoposide. A. HBZ does not alter the level of 
apoptosis induced by etoposide. HCT116 p53+/+ cells were transiently transfected with an HBZ or empty expression vector and, 48 h 
post-transfection, were treated with etoposide (ETO) or the DMSO vehicle (control) for 24 hours as indicated. Plots are from a representative 
experiment and the bar graph shows the average flow cytometry data of early apoptosis (grey bars) and late apoptosis (darker grey bars) 
from three independent experiments ± S.D. B. HBZ decreases G2/M arrest in an asynchronous cell population. HCT116 p53+/+ cells were 
transiently transfected with an HBZ or the empty expression vector and, 48 h post-transfection, were treated with etoposide (ETO), or the 
DMSO vehicle (control) for 24 hours as indicated. The graph shows the average flow cytometry data from three independent experiments 
± S.D. *P < 0.05 (two-tailed Student t test). C. HBZ delays G2/M arrest in a synchronized cell population. Transfected HCT116 p53+/+ cells 
were arrested in G1 phase by serum starvation and treated with etoposide (ETO), or the DMSO vehicle (control) for the times indicated. 
The graph shows the average flow cytometry data from two independent experiments ± S.D. 
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interferes with both processes given that HBZ inhibited 
HBO1 HAT activity in vitro and caused a reduction in 
the level of HBO1 associated with the promoter in cells. 
As with p300, the bZIP domain of HBZ interacts directly 
with HBO1 and is responsible for the inhibition of HAT 
activity. It is intriguing that HBZ is able to inhibit the 
HAT activities of both p300 and HBO1 considering the 
divergence in the amino acid sequences between their 
HAT domains. Future studies will determine whether 
HBZ targets an amino acid motif that is shared between 
these two proteins and explore the possibility that 
HBZ exhibits similar inhibitory effects on other HAT 
proteins.
The ability of HBZ to inhibit the HAT activities of 
both p300 and HBO1 is likely to affect separate events 
associated with p53-mediated transcription from the 
p21/CDKN1A promoter (Figure 8). Our data indicate 
that, by binding p300, HBZ inhibits acetylation of 
p53, thereby reducing the transcriptional activity of 
the tumor suppressor. In addition, HBZ may also affect 
the coactivator function of p300 at the p21/CDKN1A 
promoter [13, 78, 79]. Unlike p300, HBO1 has not been 
reported to acetylate p53 [59], which we confirmed in this 
study. Therefore, HBZ is likely to impede the ability of 
HBO1 to acetylate histones at the p21/CDKN1A promoter. 
Indeed, HBO1 serves as the HAT component of a protein 
complex consisting of JADE and ING proteins, in which 
it is responsible for acetylation of specific lysine residues 
in histones H3 and H4 [80]. It is possible that HBO1 and 
p300 cooperate in other nuclear processes. In Drosophila 
the concerted HAT activities of CBP and the HBO1 
orthologue, Chameau (Chm), hyperacetylate nucleosomes 
at gene amplification origins, which is required in 
the development of follicle cells [81]. In mammalian 
cells, HBO1 and p300 regulate CDT1 function. p300 
acetylates CDT1 to promote its accumulation while HBO1 
interacts with CDT1 to support its ability to recruit the 
MCM helicase [23, 82]. It would thus be of interest to 
Figure 8: Model summarizing the effects of HBZ on p53-regulated transcription of p21/CDKN1A. Etoposide-induced 
DNA damage, stimulates p53-dependent recruitment of p300 and HBO1 to the promoter (dashed blue arrows). During this process p300 
acetylates p53 at K382 (ac-labeled arrow) and other lysine residues to increase the DNA-binding activity of p53 (solid blue arrow). HBO1 
recruitment may be facilitated by associated ING and JADE/BRPF proteins, which interact with methylated histone H3 through their 
PHD finger domains. These interactions may position HBO1 in proximity to the transcription start site, where it acetylates histones. By 
inhibiting the HAT domains of p300 and HBO1, HBZ represses acetylation of p53 and promoter-associated histones. HBZ also restricts the 
recruitment of HBO1, which may lead to further reduction in acetylation of histones at the promoter. The sum of the effects of HBZ is to 
dampen the level of activation of p21/CDKN1A (and GADD45A) transcription, leading to a delay in cell cycle arrest induced by etoposide.
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characterize the potential cooperative roles of HBO1 and 
p300/CBP in replication licensing and determine whether 
HBZ affects this process.
The effects of HBZ on the transcriptional response of 
p53 is consistent with HBZ specifically counteracting cell 
cycle arrest following etoposide treatment. For example, 
acetylation of p53 at K382, which was reduced by HBZ, 
potentially favors the activation of genes involved in cell 
cycle arrest, while acetylation of p53 at K120, which was 
not affected by HBZ, has been linked to apoptosis [83]. 
Consistent with this pattern, HBZ did not affect apoptosis, 
but HBZ did dampened the G2/M phase arrest induced by 
etoposide, which is expected to involve the reduction in 
p21/CDKN1A as well as GADD45A expression. Indeed, 
p21/CDKN1A contributes to cell cycle arrest in both the 
G1 and G2 phases of the cell cycle through its ability 
to bind to and inhibit multiple cyclin/CDK complexes 
(reviewed in [73]). GADD45A participates in cell cycle 
arrest during the G2/M checkpoint, by also binding to, and 
blocking activation of cyclin/CDK complexes [74–76].
In contrast to HBZ, another HTLV-1-encoded protein, 
Tax, activates p21/CDKN1A expression, an effect that is 
independent of p53 [84]. Tax exhibits oncogenic properties 
and is believed to be essential for the development of 
ATL [28, 84]. Therefore, effects of Tax observed in 
HTLV-1-infected T-cell lines are often recapitulated in 
ATL cells from patients, which would suggest the effect 
of HBZ on p21/CDKN1A expression does not relate to 
ATL. However, unlike HTLV-1 cell lines that express high 
levels of p21/CDKN1A, expression of this gene is low to 
undetectable in ATL cell lines and ATL patient samples 
[85]. Therefore, although activation of p21/CDKN1A 
expression by Tax may occur during the course of HTLV-1 
infection, it does not appear to apply to ATL maintenance.
In addition to inducing cell cycle arrest following 
stress, p21/CDKN1A and GADD45 promote senescence 
[86], which is a process that is also associated with Tax 
[87]. One of the many functions of Tax is to stimulate 
NF-κB signaling that, when constitutively activated, 
leads to increased expression of p21/CDKN1A and the 
onset of cellular senescence [88]. Interestingly, HBZ 
inhibits NF-κB signaling [44, 89], and this function is 
reported to alleviate Tax-induced senescence [88]. Based 
on results from our current study, it is possible that 
HBZ also counteracts senescence by reducing levels of 
p21/CDKN1A and GADD45A. In addition to these 
effects, HBZ has also been reported to increase expression 
of hTERT, the catalytic subunit of human telomerase 
reverse transcriptase [90], which may support constitutive 
telomerase activity, allowing cells to bypass senescence 
[91, 92]. Therefore, HBZ potentially utilizes multiple 
pathways to prevent senescence. Overall, by bypassing 
DNA damage-induced cell cycle arrest and senescence, 
cells expressing HBZ may accumulate mutations that 
eventually contribute to the development of ATL.
MATERIALS AND METHODS
Cell culture and treatments
HCT116 p53+/+ cells [68] were cultured in McCoy’s 
5A medium, HEK293T/17 (ATCC) and HeLa-S3 clones 
[64] were cultured in DMEM, H1299 and MOLT-4 cells 
were culture in RPMI-1640 medium, and Jurkat cells 
were culture in IMDM. All media were supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin, 
50 mg/mL streptomycin, and 2 mM L-glutamine. Cells 
were incubated at 37°C in a humidified atmosphere 
containing 5% CO2. Cells were transfected using 
Turbofect (Thermo Fisher Scientific) and described 
by the manufacturer. Genotoxic drugs were used at the 
following concentrations: 50 µM etoposide (Sigma), 
10 nM actinomycin D (Sigma), or 0.2 µg/mL doxorubicin 
(Sigma). siRNA targeting HBO1 and control siRNA 
were purchased from Life Technologies (# 4390824 and 
#12935–112).
Plasmids
Empty vectors used in this study included 
pcDNA3.1-Myc-His A (Thermo Fisher Scientific), 
pGEX-2T (GE Healthcare). E. coli and mammalian 
HBZ expression vectors included GST-HBZ, GST-
HBZ bZIP, HBZ-AD1-122, pcDNA-HBZ-Myc-His, 
pcDNA-HBZ-bZIP-Myc-His and have been described 
[43, 93]. HBZ-Flag was prepared by NotI/HindIII 
excision of the HBZ cDNA from pcDNA-HBZ-Myc-His 
and insertion of the fragment into the same sites in 
pCMV-3Tag-8 (Stratagene).  pBABE-GFP-HBZ was 
prepared by digesting pcDNA-HBZ-bZIP-Myc-His with 
ScaI/PvuII and inserting the fragment extending from 
the CMV promoter to the BGH polyadenylation signal 
into the BamH1 site of pBABE-GFP that was a gift from 
William Hahn (Addgene plasmid # 10668). DNA ends 
were polished prior to ligation. Other plasmids used for 
transduction, pCL-Ampho and pHCMVG, have been 
described [94, 95]. Reporter plasmids included pRL-TK 
and pRL-SV40 from Promega, WWP-Luc (p21 promoter) 
[2] and PG13-luc (wt p53 binding sites), which was a gift 
from Bert Vogelstein (Addgene plasmid # 16442) [2]. 
E. coli and mammalian HBO1 expression vectors included 
His6-HBO1, Flag-HBO1, Flag-HBO1
G485 (HAT inactive) 
and HA-HBO1, which have been described [22, 23, 96]. 
Other expression vectors used in this study included 
pCI-Flag-p/CAF, which was a gift from Yoshihiro Nakatani 
(Addgene plasmid # 8941) [97], pcDNA3-HA-p53, 
pC53-SN3 [98]; pSG-Tax, pRSETA-p53, pCI-Flag-p300, 
Flag-MOZ and pcDNA-HA-Tip60, which have been 
described [33, 99–102]. The MOZ HAT domain was 
PCR-amplified from MYST3 and cloned into the 
BamHI/EcoRI sites of pGEX-2T (GE Healthcare). 
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MYST3 was a gift from Cheryl Arrowsmith (Addgene 
plasmid # 25181). 
Preparation of cellular extracts and western blot 
assays
Nuclear extracts were prepared from 5 × 105 cells/ 
10 cm plate transfected for 48 hours and then treated with 
drugs or carrier for 8 hours (HCT116) or 5 hours (HeLa). 
Extracts were prepared as described [44], using solutions 
additionally supplemented with Halt Phosphatase 
Inhibitor Cocktail (Thermo Scientific). Proteins from 
nuclear extracts were resolved by SDS-PAGE and 
analyzed by Western blot as described [44]. The primary 
antibodies used for protein detection were as follows: 
MOZ (39868) and H4 (39270) antibodies purchased 
from Active Motif; p300 (sc-584), p/CAF (sc-13124), 
p21 (sc-397) and p53 (sc-126) antibodies purchased from 
Santa Cruz Biotechnology; pan-acetyl lysine (9441), 
p53 K382 (2525) and H2A.X (7631) antibodies purchased 
from Cell Signaling; p53 K320 (06-1283), p53 K120 
(ABE286), Myc (clone 4A6, 05–724), acetyl H4 
(06–866), actin (clone C4, MAB1501) and ser139-H2A.X 
(05–636) antibodies purchased from EMD Millipore; 
6 × His (ab9108) antibody purchased from Abcam; Flag 
(M2, F3165) and HA (clone HA-7, H3663) antibodies 
purchased from Sigma-Aldrich; Tip60 (GTX112198) and 
HBO1 (N2C1, GTX102041) purchased from Genetex; and 
Tax hybridoma (168B17–46–92) obtained from the NIH 
AIDS Research and Reference Reagent Program.
RNA extraction, cDNA synthesis and 
quantitative real-time PCR
Cells were transfected and treated as described 
above. RNA was extracted using TRIzol Reagent 
(Thermo Fisher Scientific). cDNA was synthesized 
with random hexamers using the RevertAid kit 
(Thermo Fisher Scientific). Quantitative real-time 
PCR was performed and analyzed as described [64]. 
Primers used were as follows: UBE2D2 F: TGCCTG 
AGATTGCTCGGATCTACA, UBE2D2 R: ACTTCTGAG 
TCCATTCCCGAGCTA, RRM2B F: GAGGAGCTCAG 
TTCCCTCAG, RRM2B R: TTCGTTGGTGTCTGAAG 
ATGA, BID F: GAGGAGCACAGTGCGGAT, BID R: GG 
AACCGTTGTTGACCTCAC, CDKN1A F: ACCATGTG 
GACCTGTCACTGCTT, CDKN1A R: AGAAGATGT 
AGAGCGGGCCTTGA, NOXA F: TGCAGGACTGT 
TCGTGTTCAGCTC, NOXA R: AGTAGCACACTCGAC 
TTCCAGCTCT, GADD45A F-a: GTGCTGGTGACGAAT 
CCACATTCA, GADD45A R-a: TGCCATCACCGTTCA 
GGGAGATTA, GADD45A F-b: GAGAGCAGAAGACC 
GAAAGGA, GADD45A R-b: CACAACACCACGT 
TATCGGG, BAX F: GGGTTGTCGCCCTTTTCTAC, 
BAX R: GGAGGAAGTCCAATGTCCAG, PUMA F: GAC 
GACCTCAACGCACAGTA, PUMA R: GTAAGGGCAG 
GAGTCCCAT, MDM2 F: TGTTGTGAAAGAAGCAGTA 
GCA, MDM2 R: CCTGATCCAACCAATCACCT, FAS F: 
TTTCACTTCGGAGGATTGCT, FAS R: TTGATGTCAG 
TCACTTGGGC, PIRH2 F: CACTGTGAAAACTGTGGA 
ATTTG, and PIRH2 R: ACACTTGTGTCTTCCTTGA 
AGATT. 
Luciferase assays
Cells were transfected in 24-well plates (6 × 104 
cells/well) using 1 µg of DNA/sample, which included 
10 ng of pRL-TK or 1 ng of pRL-SV40 control reporter 
plasmid (Promega) using Turbofect or Lipofectamine 
2000. Samples were processed and analyzed as described 
[103]. Lysates (12 µl or 30 µl) were also analyzed by 
Western blot.
Cell transduction
HEK293T/17 cells were seeded at 6 × 106 cells 
on 10 cm plates. Cells were transfected with 7.5 pmol 
pBABE-GFP or pBABE-GFP-HBZ, 20 μg (2.5 pmol) 
pCL-Ampho and 6.7 μg pHCVG using calcium phosphate. 
The medium in each plate was replaced with 10 mL of 
supplemented DMEM 24 hours post-transfection, which 
was replaced with 6 mL of supplemented RPMI-1640 
24 hours later. After an additional 24 hours, the culture 
medium was passed through a 0.2 μm polysulfone 
filter and used to transduce 3 × 106 MOLT-4 cells. 
Three milliliters of supplemented RPMI was added to 
each 6 mL culture, and Polybrene was then added to a 
final concentration of 16 ug/mL. Twenty four hours 
post-transduction, the medium was replaced with 10 mL 
of supplemented RPMI-1640. Twenty four hours later, 
cultures were treated with DMSO or etoposide for 5 hours.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as previously 
described [23]. Crosslinked chromatin was extracted in 
Run-on-Lysis buffer (10 mM Tris-HCl pH 7.5; 10 mM 
NaCl; 3 mM MgCl2; 0.5% NP-40) and then sheared 
by sonication (Misonix Sonicator 3000) on ice to an 
average length of 400bp.  After pre-clearing with a mix 
of protein A/G sepharose beads (4°C for 3 hours), the 
chromatin from an equivalent of 5 × 107 cells was used 
for immunoprecipitation with antibodies against HBO1 
(ab70183, Abcam), which has been characterized [18], 
and p53 (sc-126, Santa Cruz Biotechnology) or IgG 
as a control. Immunoprecipitates were eluted in buffer 
E (25 mM Tris-HCl pH 7.5; 5 mM EDTA; 0.5% SDS) 
and cross-links reversed at 65°C with proteinase K for 
6 hours. Resulting naked DNA was then purified using the 
QIAquick PCR purification kit (Qiagen) and DNA eluted 
in 100 µl distilled water.
Quantitative real-time PCR was performed using 
SYBR Green I. Enrichment for a specific DNA sequence 
Oncotarget1701www.impactjournals.com/oncotarget
was calculated using the comparative Ct method as 
previously described [104]. Data are normalized to 
histone H3 exon 2 background binding and expressed 
as occupancy value (occupancy). Experiments were 
performed in triplicate. PCR primer pairs are as 
follows: BDNF: GTAAAGCCAACCCTGTGTCG, 
TCCGCTCCAAAATCTGACTC; HOXA9: CGCCAACC 
AAACACAACAGT, AAGTCGGAAACGACCAACAG; 
Histone H3: CCAAATGCTGGCATTGTCC, AGTTTT 
TCCATTTTCATTTGTGTGTG; p21/CDKN1A: GCTG 
AGCCTCCCTCCATCCCTATGC, TAGAGGTCTCCTGT 
CTCCTACCATC; p21/CDKN1A p53 RE 5′: AGCAGGC 
TGTGGCTCTGATT, CAAAATAGCCACCAGCCTCT 
TCT; p21/CDKN1A p53 RE 3′: CTGTCCTCCCCGAG 
GTCA, ACATCTCAGGCTGCTCAGAGTCT; p21/CDK 
N1A TSS: TATATCAGGGCCGCGCTG, GGCTCCA 
CAAGGAACTGACTTC; p21/CDKN1A coding region: 
CCAGGAAGGGCGAGGAAA, GGGACCGATCCTAGA 
CGAACTT and GADD45A: TTCATCTCGCCTGGCTTT 
TT, AGCAAACAAGGTTTTTGTGGGTT.
Immunoprecipitation assays
HEK293T/17 (1.5 × 106 cells/10 cm plate) 
were transfected for 24 hours, and whole cell extracts 
were prepared as described [51]. Proteins were then 
immunoprecipitated from 200–400 μg of whole cell 
extracts as described [93] and analyzed by Western 
blot. For immunoprecipitation of endogenous HBO1, 
HBZ-Flag was transfected into H1299 cells for 48 
hours, nuclear extracts were then prepared and HBZ 
was immunoprecipitated with Flag-resin (A2220, 
Sigma-Aldrich). 
GST pull-down assays
GST, GST-HBZ and GST-HBZ-bZIP were 
expressed and purified as described [93]. His6-HBO1 
was expressed in E. coli and purified as described [103]. 
Purified proteins were dialyzed in HM 0.1 (20 mM 
HEPES [pH 7.9], 0.1 M KCl, 12.5 mM MgCl2, 1 mM 
EDTA, 20% [vol/vol] glycerol, 0.025% [vol/vol] Nonidet 
P40, and 1 mM DTT). Glutathione-agarose beads were 
equilibrated in 0.5x Superdex buffer (12.5 mM HEPES 
[pH 7.9], 75 mM KCl, 6.25 mM MgCl2, 5 μM ZnSO4, 
20% [vol/vol] glycerol, 0.05% [vol/vol] Nonidet P40, 
1 mM EDTA and 1 mM DTT) and incubated with 25 pmol 
of GST proteins at 4°C for 1 h. Beads were then washed 
twice with 0.5 × Superdex buffer and combined with 10 
pmol of His-HBO1. Binding reactions were mixed at 4°C 
overnight, and beads were subsequently washed four times 
with 0.5 × Superdex buffer and resuspended in loading 
buffer. Eluted proteins were resolved by SDS-PAGE and 
detected by Western blot.
In vitro HAT assay
HAT assays were performed as described [44] with 
incubation times and specified protein amounts indicated 
in the figure legends. Recombinant proteins p300, HBZ, 
HBZ-AD1-122, HBZ-bZIP and histones were described 
previously [44]. Recombinant protein HBO1 was obtained 
from SignalChem Pharmaceuticals Inc. (specific activity 
of 0.4 nmol/min/mg). p53 was expressed in E. coli, and 
the bacterial cell pellet was resuspended in lysis buffer 
(20 mM Tris [pH 8.0], 0.5 mM EDTA, 0.5 M KCl, 10% 
[vol/vol] glycerol, 1% [vol/vol] Nonidet P40, 10 mM 
2-mercaptoethanol and 0.5 mM PMSF) and sonicated. 
The cleared lysate was then batch-loaded onto nickel-NTA 
agarose beads (Qiagen) and eluted with a 10 mM to 0.5 M 
linear imidazole gradient (supplemented lysis buffer 
containing 0.1 M KCl). Peak p53 fractions were combined, 
dialyzed into HM 0.1, batch-loaded onto heparin-agarose 
beads (Bio-Rad Laboratories), and eluted with a 0.1 to 
1 M KCl gradient (supplemented HM). MOZ-HAT was 
expressed in E. coli and purified using Ni-NTA agarose 
beads (Qiagen) as described [103]. Eluted proteins were 
dialyzed into HM 0.1.
Cell cycle and apoptosis analyses
HCT116 p53+/+ cells were seeded at 5 × 105 cells in 6 
well plates. Unsynchronized cells were treated with drugs 
or carrier 48 hours after transfection then harvested at 
indicated time points with phosphate-buffered saline (PBS) 
and 5 mM EDTA. To synchronize cells, 24 hours after 
transfection, cultures were switched to serum-free medium 
for 48 hours. Cells were released from growth-arrest 
by addition of serum, then treated with drug or carrier 
before harvesting in PBS/5 mM EDTA at the indicated 
time points. Cells were washed and resuspended in PBS, 
fixed in 70% ethanol, stained with 50 mg/mL propidium 
iodide (Sigma), treated with RNase A (Sigma) and then 
incubated at 25°C for 30 minutes. Fluorescence was 
measured by flow cytometry using BD LSR II flow 
cytometer (BD Biosciences) and data were analyzed with 
ModFit LT (Verity). For Annexin V/PI staining, 48 hours 
after transfection, cells were washed and then treated 
with drug or carrier for 24 hours. Cells were subsequently 
stained using the Dead Cell Apoptosis Kit with Annexin 
V FITC and PI for flow cytometry (Life Technologies). 
Fluorescence was measured by flow cytometry using BD 
LSR II flow cytometer (BD Biosciences) and data were 
analyzed with FlowJo (FlowJo LLC).
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